EFFICACY AND SAFETY OF SULBACTAM–DURLobactam VERSUS COLISTIN FOR THE TREATMENT OF PATIENTS WITH SERIOUS INFECTIONS CAUSED BY ACINETOBACTER BAUMANNII–CALCOACETICUS COMPLEX: A MULTICENTRE, RANDOMISED, ACTIVE-CONTROLLED, PHASE 3, NON-INFERIORITY CLINICAL

Keith S Kaye, Andrew F Shorr, Richard G Wunderink, Bin Du, Gabrielle E Poirier, Khurram Rana, Alita Miller, Drew Lewis, John O'Donnell, Lan Chen, Harald Reinhart, Subasree Srinivasan, Robin Isaacs, David Altarac

The ATTACK trial was conducted across 59 clinical sites in 16 countries, focusing on adults with laboratory-confirmed hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The study aimed to assess the non-inferiority of sulbactam–durlobactam compared to colistin, both administered with imipenem–cilastatin as background therapy. The primary endpoint was 28-day all-cause mortality, with results indicating that sulbactam–durlobactam was non-inferior to colistin in this patient population.